Comprehensive Research Solutions for CCHFV Studies
As a WHO-priority pathogen, Crimean-Congo Hemorrhagic Fever Virus (CCHFV) remains one of the most significant emerging zoonotic threats, characterized by a high case fatality rate and an expanding geographic distribution (Kausha et al., 2025). The persistent and growing public health challenge posed by CCHFV is starkly underscored by recent outbreaks in 2026, which highlight the critical need for innovative research and surveillance tools.
In February 2026, new cases were confirmed in Senegal and Uganda (UK Health Security Agency, 2026), while Iraq has reported 152 confirmed cases, including nine deaths, as of June 2026, with Dhi Qar province particularly hard-hit. A case was also reported in Spain in June 2026 (KDHE Weekly Domestic and International Infectious Disease Report, 2026). These reports are a clear reminder that the virus' range is expanding, necessitating a concerted, global research response.
Explore the complete portfolio of CCHFV research solutions available to identify tools suited to specific research needs.
Scientific Solutions: A Portfolio of Enabling Tools for CCHFV Studies
Recombinant Proteins
A comprehensive portfolio of recombinant CCHFV proteins is available to support viral entry studies, immunogenicity profiling, diagnostic assay development, and therapeutic lead discovery.
Key proteins include
- Nucleoprotein: a highly conserved immunodominant target for serological surveillance and NP-specific antibody therapeutics
- Glycoprotein/envelopment polyprotein: essential for studying viral attachment, receptor interactions, and neutralizing antibody responses.
ELISA Kits
A range of quantitative ELISA kits is available for CCHFV serological studies, enabling detection and measurement of IgG and IgM antibodies across multiple species—including human, mouse, rabbit, goat, sheep, and bovine.
These assays are essential for seroprevalence surveillance, outbreak investigations, vaccine immunogenicity assessment, and understanding humoral immune responses in both natural hosts and animal models.
Primary Antibody
A diverse portfolio of antibodies targeting CCHFV structural proteins—nucleoprotein (NP) and glycoprotein (GP/Gc)—is available to support diagnostic assay development, antigen detection, and therapeutic lead discovery. The NP, a highly conserved and immunodominant antigen, is a key target for serological assays and has recently emerged as a promising candidate for cross-protective antibody-based therapeutics. The GP/Gc proteins, critical for viral entry, are essential for studying neutralizing antibody responses and vaccine immunogenicity.
Inhibitors
CCHFV-IN-1 is available as a research-grade compound for antiviral drug discovery and mechanism-of-action studies.
This small molecule inhibitor is designed for use in in vitro efficacy screening, viral replication assays, and lead optimization studies aimed at identifying potential therapeutic candidates against CCHFV.
Real-time RT-PCR kit
A real-time RT-PCR kit is available for the molecular detection of CCHFV.
This assay enables rapid and sensitive identification of viral RNA, supporting diagnostic confirmation, outbreak investigation, and surveillance efforts—critical needs given the challenges of current diagnostics, which can require 2-5 days for results, and the WHO's prioritization of improved point-of-care testing.
Advance Your CCHFV Research with Confidence
Accelerate your Crimean-Congo Hemorrhagic Fever Virus research with a comprehensive portfolio of proteins, antibodies, ELISA kits, RT-PCR assays, and small-molecule inhibitors.
If you don't find the specific product you need, we can still provide it upon request.